Emerging treatments for age-related macular degeneration

20 September 2017
Volume 18, Issue 3

This narrative review summarises emerging interventions that may be mentioned in the popular and professional press, and may be on our menu of treatment options to discuss with patients in the near future.


When optometry and medical students are taught at university, a dramatic caveat should be added to much of what they learn: that it will be of no use in their careers to come. Knowledge is constantly replaced or updated, and clinical skills are at risk of being superseded by technology: for example, the time-honoured art of direct ophthalmoscopy may be on the verge of redundancy (Purbrick and Chong 2015). Age-related macular degeneration (AMD) is the commonest cause of visual impairment in the western world, and is becoming an increasing public health challenge in Asia (Velez-Montoya et al. 2014). The management of AMD underwent a paradigm shift in 2006 with the advent of antivascular endothelial growth factor treatments (anti-VEGFs) and optical coherence tomography (OCT).

Sign in to continue

Forgotten password?

Not already a member of The College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

Seek out cutting-edge clinical content to address new challenges, says Kieran Loft MCOptom.

This edition takes a look at the risk variants and genetic distribution of Age-related macular degeneration as well as topical ivermectin-metronidazole gel therapy for blepharitis caused by Demodex.

Increasing demand for intravitreal injections to treat conditions such as wet AMD provides an opportunity for optometrists to widen their portfolio of skills, writes Kim Thomas.